AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3723570 — intervention group
Group type: COMPARATOR
Intervention: Self-guided critiques using a written checklist
Number of subjects: 105
Study 3723570 — intervention group
Group type: COMPARATOR
Intervention: No critiques (control group)
Number of subjects: 105
Study 31042402 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 11
Study 31042402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 11
Study 28602159 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger wine glass (370 ml)
Number of subjects: 166
Study 28602159 — intervention group
Group type: COMPARATOR
Intervention: Smaller wine glass (250 ml)
Number of subjects: 166
Study 25881226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist based intervention including phone‐based pharmacist intervention, pharmacist‐physician collaboration, patient education, and a CKD registry
Number of subjects: 2199
Study 25881226 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2199
Study 25881226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist based intervention
Number of subjects: 2199
Study 23703604 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication self-management education program (5 sessions including verbal education, 1:1 consultation, practice in medication self-management, and discussion)
Number of subjects: 49
Study 23703604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 21726257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg/day) plus aspirin (100 mg/day)
Number of subjects: 218
Study 21726257 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole (20 mg/day) plus clopidogrel (75 mg/day)
Number of subjects: 218
Study 18826422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task performance in patients with aMCI
Number of subjects: 0
Study 18826422 — intervention group
Group type: COMPARATOR
Intervention: Dual task performance in elderly controls
Number of subjects: 0
Study 18826422 — intervention group
Group type: EXPERIMENTAL
Intervention: PET activation in left inferior frontal region during dual task performance in patients with aMCI
Number of subjects: 0
Study 18826422 — intervention group
Group type: COMPARATOR
Intervention: PET activation in left inferior frontal region during dual task performance in elderly controls
Number of subjects: 0
Study 16393593 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm cryogen‐cooled pulsed dye laser treatment
Number of subjects: 16
Study 16393593 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated portion of the scar)
Number of subjects: 16
Study 15459593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem ER tablets (240 mg titrated to 360 mg and to 540 mg)
Number of subjects: 261
Study 15459593 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg titrated to 10 mg and to 20 mg)
Number of subjects: 261
Study 15459593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem ER tablets
Number of subjects: 261
Study 15459593 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 261
Study 11263782 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) with or without cyclophosphamide (CYC)
Number of subjects: 278
Study 11263782 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (CS) alone
Number of subjects: 278
Study 11263782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 278
Study 11263782 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B virus (HBV)‐related PAN
Number of subjects: 278
Study 11263782 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 278
Study 9378194 — intervention group
Group type: EXPERIMENTAL
Intervention: DDIR pacing mode
Number of subjects: 79
Study 9378194 — intervention group
Group type: COMPARATOR
Intervention: DDI pacing mode
Number of subjects: 79
Study 9378194 — intervention group
Group type: COMPARATOR
Intervention: DDI + DDIR pacing modes
Number of subjects: 79
Study 8354536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) + Propantheline bromide (15 mg) at bedtime
Number of subjects: 161
Study 8354536 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg) at bedtime
Number of subjects: 161
Study 3728125 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment program consisting of communication and counseling skills, assertiveness training, and moral dilemmas.
Number of subjects: 54
Study 3728125 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study 28678033 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy (MRT)
Number of subjects: 41
Study 28678033 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 41
Study 26811178 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin (GC)
Number of subjects: 55
Study 26811178 — intervention group
Group type: COMPARATOR
Intervention: docetaxel/carboplatin (DC)
Number of subjects: 55
Study 24994700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (n = 38): Chest tubes removed if PrRPl/B ≤0.5, regardless of daily drainage.
Number of subjects: 72
Study 24994700 — intervention group
Group type: COMPARATOR
Intervention: Group C (n = 34): Chest tubes removed if daily drainage ≤250 ml, regardless of protein content.
Number of subjects: 72
Study 24994700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S vs Group C: Mean chest tube removal time.
Number of subjects: 72
Study 24994700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S vs Group C: Median hospital stay.
Number of subjects: 72
Study 24994700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S: Patients with high protein content preventing removal despite acceptable volume of daily drainage.
Number of subjects: 72
Study 23232895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (750 mg/d) + autoCPAP
Number of subjects: 51
Study 20694273 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to a target INR of 2.0-3.0)
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg bid
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg bid
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg qd
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg qd
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (both 30 and 60 mg qd)
Number of subjects: 1146
Study 20694273 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1146
Study 18245547 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine
Number of subjects: 80
Study 18245547 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (Control)
Number of subjects: 80
Study 16813794 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with acetic acid-guided biopsies
Number of subjects: 31
Study 16813794 — intervention group
Group type: COMPARATOR
Intervention: Standard video endoscopy with random biopsies
Number of subjects: 31
Study 12629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 161
Study 12629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 161
Study 12629372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 10945085 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision Register policy (registered patients)
Number of subjects: 259
Study 10945085 — intervention group
Group type: COMPARATOR
Intervention: Comparison patients (upper tier of the Care Programme Approach)
Number of subjects: 259
Study 10945085 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' views on the Supervision Register policy
Number of subjects: 259
Study 9103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus physical exercise (BEX; n = 72)
Number of subjects: 205
Study 9103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus nicotine gum (BNIC; n = 63)
Number of subjects: 205
Study 9103749 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) American Lung Association quit program plus nicotine anonymous meetings (n = 70)
Number of subjects: 205
Study 9103749 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BEX, BNIC, ST)
Number of subjects: 205
Study 8250305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HS)/placebo (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine (HS)/20 mg of famotidine (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine (HS)/placebo (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (HS)/20 mg of famotidine (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine (HS)/40 mg of famotidine (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine (HS)/placebo (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (HS)/40 mg of famotidine (AM)
Number of subjects: 322
Study 8250305 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (HS and AM or AM only)
Number of subjects: 322
Study 3892672 — intervention group
Group type: EXPERIMENTAL
Intervention: Paractol flüssig
Number of subjects: 20
Study 3892672 — intervention group
Group type: COMPARATOR
Intervention: Sab simplex
Number of subjects: 20
Study 30139340 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous infusion of somatostatin for 6 days
Number of subjects: 152
Study 30139340 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 6 days
Number of subjects: 152
Study 27386006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dill seed oil mouthrinse
Number of subjects: 90
Study 27386006 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthrinse (Hexodent)
Number of subjects: 90
Study 24880672 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonosurgery/voice therapy
Number of subjects: 40
Study 22672686 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% aluminum particle filled PMMA
Number of subjects: 10
Study 22672686 — intervention group
Group type: COMPARATOR
Intervention: unfilled PMMA
Number of subjects: 10
Study 22672686 — intervention group
Group type: EXPERIMENTAL
Intervention: aluminum and silver fillers in concentrations of 10%, 20%, and 30%
Number of subjects: 10
Study 22672686 — intervention group
Group type: EXPERIMENTAL
Intervention: silane-treated metalized PMMA at 30% concentration
Number of subjects: 10
Study 20356558 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 75
Study 20356558 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% NaCl solution
Number of subjects: 75
Study 20356558 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaCl solution
Number of subjects: 75
Study 20356558 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl solution
Number of subjects: 75
Study 20356558 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control group)
Number of subjects: 75
Study 19029562 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine plus midazolam (1 mg/kg ketamine + 0.1 mg/kg midazolam; IVKM)
Number of subjects: 99
Study 19029562 — intervention group
Group type: COMPARATOR
Intervention: IV ketamine only (1 mg/kg; IVK)
Number of subjects: 99
Study 15718178 — intervention group
Group type: EXPERIMENTAL
Intervention: C+HBI
Number of subjects: 106
Study 15718178 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 106
Study 12873948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus diclofenac (100 mg tramadol and 75 mg diclofenac IM)
Number of subjects: 120
Study 12873948 — intervention group
Group type: COMPARATOR
Intervention: Tramadol plus placebo (100 mg tramadol IM)
Number of subjects: 120
Study 12873948 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac plus placebo (75 mg diclofenac IM)
Number of subjects: 120
Study 12873948 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (tramadol plus diclofenac)
Number of subjects: 120
Study 12873948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus diclofenac
Number of subjects: 120
Study 12873948 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study 11798619 — intervention group
Group type: EXPERIMENTAL
Intervention: mecobalamin 500 microg intramuscularly three times a week for four weeks then followed by 500 microg orally three times a day for additional eight weeks
Number of subjects: 108
Study 11798619 — intervention group
Group type: COMPARATOR
Intervention: vitamin B(12)
Number of subjects: 108
Study 11798619 — intervention group
Group type: EXPERIMENTAL
Intervention: mecobalamin
Number of subjects: 108
Study 8601552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU b.i.d.)
Number of subjects: 35
Study 8601552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1746779 — intervention group
Group type: EXPERIMENTAL
Intervention: Transderm scopolamine
Number of subjects: 201
Study 1746779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 6138055 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam (1.0 mg)
Number of subjects: 8
Study 6138055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body weight)
Number of subjects: 8
Study 6138055 — intervention group
Group type: EXPERIMENTAL
Intervention: Loprazolam (1.0 mg) + Alcohol (0.7 g/kg body weight)
Number of subjects: 8
Study 31894413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity intermittent exercise in the heat (400 W, 15-min bouts with 15-min recovery)
Number of subjects: 33
Study 31894413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity intermittent exercise in the heat
Number of subjects: 33
Study 31189966 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea treatment (any type)
Number of subjects: 47738
Study 31189966 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 47738
Study 31189966 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 47738
Study 29127562 — intervention group
Group type: EXPERIMENTAL
Intervention: Active videogame for 30 min, once a week for 6 weeks
Number of subjects: 28
Study 29127562 — intervention group
Group type: COMPARATOR
Intervention: Sedentary videogame for 30 min, once a week for 6 weeks
Number of subjects: 28
Study 27593569 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy sessions
Number of subjects: 49
Study 27593569 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused therapy sessions
Number of subjects: 49
Study 27593569 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-focused therapy sessions
Number of subjects: 49
Study 25152474 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve delivered by subclavian artery (n = 70)
Number of subjects: 150
Study 25152474 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve delivered by direct aortic approach (n = 80)
Number of subjects: 150
Study 22170010 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (± thiazide‐diuretics)
Number of subjects: 252
Study 22170010 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (± thiazide‐diuretics) with diuretics
Number of subjects: 252
Study 20122030 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist communication with older patients
Number of subjects: 180
Study 17470267 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to promote childbirth companions in 5 hospitals
Number of subjects: 2000
Study 17470267 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 hospitals without the educational intervention)
Number of subjects: 2000
Study 15089025 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lift group
Number of subjects: 198
Study 15089025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 12205249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse
Number of subjects: 735
Study 12205249 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional
Number of subjects: 735
Study 12205249 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study 11477829 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangxinling liquid extract (QXLLE)
Number of subjects: 90
Study 11477829 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangxinling liquid extract (QXLLE) plus small dose of digoxin
Number of subjects: 90
Study 11477829 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 90
Study 11477829 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 11477829 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 90
Study 8586726 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR detection of CMV DNA in serum
Number of subjects: 52
Study 8586726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 2694331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octatropine-methyl-bromide and sulglycotide salt (GVP)
Number of subjects: 40
Study 2694331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 355877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration (intramuscularly)
Number of subjects: 40
Study 355877 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin E)
Number of subjects: 40
Study 31862739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0
Study 31862739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% ganciclovir
Number of subjects: 0
Study 31862739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27725233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection (10 cc)
Number of subjects: 30
Study 26542471 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Evaluation and Referral Assistant (HERA)
Number of subjects: 421
Study 26542471 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Evaluation and Referral Assistant (HERA) with faxed referral
Number of subjects: 421
Study 26542471 — intervention group
Group type: COMPARATOR
Intervention: Minimal-treatment Control
Number of subjects: 421
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: RA appendage ON (n=98)
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: RA appendage OFF (n=99)
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: RA septum ON (n=92)
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: RA septum OFF (n=96)
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing ON
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing OFF
Number of subjects: 385
Study 23868858 — intervention group
Group type: EXPERIMENTAL
Intervention: RA septum pacing
Number of subjects: 385
Study 23868858 — intervention group
Group type: COMPARATOR
Intervention: RA appendage pacing
Number of subjects: 385
Study 21411291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherm water-circulating cooling device
Number of subjects: 0
Study 21411291 — intervention group
Group type: COMPARATOR
Intervention: Conventional cooling by cold packs
Number of subjects: 0
Study 19634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 160
Study 17668528 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid-containing combination regimens with oral antibiotics
Number of subjects: 0
Study 17668528 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid-containing combination regimens with topical benzoyl peroxide and antibiotics
Number of subjects: 0
Study 17668528 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncomparative studies of retinoid-containing regimens
Number of subjects: 0
Study 14871220 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20
Study 14871220 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 20
Study 14871220 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid-PDT
Number of subjects: 20
Study 14871220 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser and PDT
Number of subjects: 20
Study 11260098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound perfusion of local bupivacaine 0.5 per cent for 60 hours
Number of subjects: 70
Study 11260098 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous morphine infusion on demand (PCA group)
Number of subjects: 70
Study 9557932 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg once daily
Number of subjects: 20
Study 9557932 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg once daily
Number of subjects: 20
Study 9557932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 7849233 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (solution)
Number of subjects: 14
Study 7849233 — intervention group
Group type: COMPARATOR
Intervention: Formulation A (powder)
Number of subjects: 14
Study 3071461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (up to 80 mg daily)
Number of subjects: 24
Study 3071461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3071461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (8 weeks administration)
Number of subjects: 24
Study 28562435 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) treatment
Number of subjects: 114
Study 28562435 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 114